LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

FibroBiologics Receives HREC Approval for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers...

November 20
Last Trade: 0.36 0.01 3.05

HOUSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts...Read more


Clearmind Medicine Accelerate FDA-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site

November 20
Last Trade: 0.21 0.0065 3.21

Prestigious Hadassah Medical Center Joins Yale, Johns Hopkins, Tel Aviv Sourasky and IMCA, in Evaluating the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate Vancouver, Canada, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND),...Read more


Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist...

November 19
Last Trade: 33.32 0.01 0.03

BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing Topline clinical data expected in 2026 PLYMOUTH MEETING, Pa. / Nov 19, 2025 / Business Wire...Read more


Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

November 20
Last Trade: 1.64 -0.19 -10.33

FDA Response Streamlines Path to Commercial Production of PF614 SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system...Read more


U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or...

November 20
Last Trade: 7.82 0.06 0.77

Following Priority Review, the U.S. FDA granted HYRNUO® (sevabertinib) approval for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by...Read more


EDAP TMS Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU 

November 20
Last Trade: 2.49 0.26 11.66

EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU  AUSTIN, Texas, November 20, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance...Read more


Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Nutex Health 38.81 34.59 $151.00
Regeneron Pharmaceuticals 34.50 4.91 $737.26
Mettler-Toledo 16.75 1.19 $1,421.18
Exact Sciences 15.28 17.73 $101.46
argenx 12.19 1.33 $926.78
IDEXX Laboratories 10.54 1.51 $707.64
PACS Group 9.78 58.11 $26.61
Guardant Health 9.48 9.52 $109.03
Natera 8.95 4.10 $227.30
Medpace 8.50 1.44 $600.68
Madrigal Pharmaceuticals 8.40 1.51 $564.00
Intuitive 7.82 1.38 $572.46
Vertex Pharmaceuticals 7.36 1.75 $428.39
Movano Health 7.13 229.26 $10.24
GRAIL 7.03 7.99 $95.00
iRhythm Technologies 6.70 4.00 $174.00
Abivax 5.83 5.16 $118.78
Waters 5.55 1.48 $381.80

Highest Volume

 
CompanyVolumeLast Trade
Mobile-health Network Solutions 41,334,299 $2.60
Exact Sciences 31,178,830 $101.46
Plus Therapeutics 17,307,545 $0.51
Applied Therapeutics 8,688,155 $0.29
Pfizer 8,108,632 $24.69
Psyence Biomedical 7,569,202 $2.12
InMed Pharmaceuticals 6,186,487 $1.36
PACS Group 5,597,839 $26.61
4,750,028 $4.23
Clearmind Medicine 4,486,240 $0.21
Nuvation Bio 4,450,445 $7.22
Nano-X Imaging 2,969,444 $3.73
Can-Fite BioPharma 2,740,723 $0.35
Sangamo Therapeutics 2,642,977 $0.42
Moderna 2,612,471 $23.98
Novo Nordisk 2,553,322 $49.17
Annexon 2,498,998 $4.81
Abbott 2,447,077 $123.82
Olema Oncology 2,334,002 $23.79
  • Upcoming FDA Catalysts

    • Ascendis Pharma (NASDAQ: ASND) PDUFA Date

      November 30, 2025
    • Kura Oncology (NASDAQ: KURA) PDUFA Date

      November 30, 2025
    • Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

      December 5, 2025
    • Milestone Pharmaceuticals (NASDAQ: MIST) PDUFA Date

      December 13, 2025
    • Innoviva (NASDAQ: INVA) PDUFA Date

      December 15, 2025
    • Aldeyra Therapeutics (NASDAQ: ALDX) PDUFA Date

      December 16, 2025

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities: